ACOG Practice Bulletin No. 83: Management of adnexal masses

Obstetrics and Gynecology

Volumn 110, Issue 1, 2007, Pages 201-214

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; INHIBIN A; INHIBIN B; LACTATE DEHYDROGENASE; ORAL CONTRACEPTIVE AGENT;

ADNEXA DISEASE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYST FLUID; DOPPLER FLOWMETRY; HUMAN; HYSTERECTOMY; IMAGING SYSTEM; LAPAROSCOPIC SURGERY; LAPAROTOMY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARIECTOMY; OVARY CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY;

ADNEXA UTERI; ADNEXAL DISEASES; ADULT; AGE FACTORS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 34347354446     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000263913.92942.40     Document Type: Review

References (116)

1. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55:S4-14. (Level III)
2. Koonings P, Campbell K, Mishell D, Daniel R, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989;74(6):921-6. (Level II-3).
3. Reis LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. editors. SEER cancer statistics review, 1975-2003. Bethesda (MD): National Cancer Institute; 2006. Available at: http://seer.cancer.gov/csr/1975_2003. Retrieved February 16, 2007. (Level III)
4. American Cancer Society, Cancer facts and figures 2007. Atlanta (GA): ACS; 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured. pdf. Retrieved February 16, 2007. (Level III)
5. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. Int J Gynaecol Obstet 2003;83(suppl 1):135-66. (Level II-3)
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30. (Level II-3)
7. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. Hereditary Ovarian Cancer Clinical Study Group. JAMA 2006;296:185-92. (Level II-2)
8. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81(2):214-8. (Level II-2)
9. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004;82:405-14. (Level II-2)
10. Kumle M,Weiderpass E, Braaten T, Adami HO, Lund E. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 2004;90:1386-91. (Level II-2)
11. Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004;91:1911-5. (Level II-2)
12. Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005;88:84-8. (Level II-3)
13. Timmerman D, Schwarzler P, Collins WP, Claerhout F, Coenen M, Amant F, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13:11-6. (Level III)
14. Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990;37:224-9. (Level III)
15. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-6. (Level II-3)
16. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11. (Level II-2)
17. Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study [published erratum appears in Ultrasound Obstet Gynecol 1998;11:v]. Ultrasound Obstet Gynecol 1997;10:192-7. (Level II-3)
18. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170:81-5. (Level II-3)
19. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72:659-64. (Level III)
20. Mol BW, Boll D, De Kanter M, Heintz AP, Sijmons EA, Oei SG, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162-7. (Level II-3)
21. Alcazar JL, Merce LT, Laparte C, Jurado M, Lopez-Garcia G. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol 2003;88:685-92. (Level II-2)
22. Caruso A, Caforio L, Testa AC, Ciampelli M, Panici PB, Mancuso S. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63:184-91. (Level II-2)
23. Agency for Healthcare Research and Quality. Management of adnexal mass. Evidence Based Report/Technology Assessment No. 130. AHRQ Publication No. 06-E004. Rockville (MD): AHRQ; 2006. (Level II-2)
24. DePriest PD, Varner E, Powell J, Fried A, Puls L, Higgins R, et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994;55(2):174-8. (Level III)
25. Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. Eur J Gynaecol Oncol 2004;25:442-4. (Level III)
26. Antonic J, Rakar S. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Eur J Gynaecol Oncol 1996;17:29-35. (Level II-3)
27. Alcazar JL, Errasti T, Zornoza A, Minguez JA, Galan MJ. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses. Int J Gynaecol Obstet 1999;66:255-61. (Level III)
28. Itakura T, Kikkawa F, Kajiyama H, Mitsui T, Kawai M, Mizutani S. Doppler flow and arterial location in ovarian tumors. Int J Gynaecol Obstet 2003;83:277-83. (Level II-2)
29. Marret H, Ecochard R, Giraudeau B, Golfier F, Raudrant D, Lansac J. Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models. Ultrasound Obstet Gynecol 2002;20:597-604. (Level II-3)
30. Stein SM, Laifer-Narin S, Johnson MB, Roman LD, Muderspach LI, Tyszka JM, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995;164:381-6. (Level II-3)
31. Schneider VL, Schneider A, Reed KL, Hatch KD. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81:983-8. (Level II-3)
32. Alcazar JL, Lopez-Garcia G. Transvaginal color Doppler assessment of venous flow in adnexal masses. Ultrasound Obstet Gynecol 2001;17:434-8. (Level II-3)
33. Marret H, Sauget S, Giraudeau B, Body G, Tranquart F. Power Doppler vascularity index for predicting malignancy of adnexal masses. Ultrasound Obstet Gynecol 2005;25:508-13. (Level II-3)
34. Alcazar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol 2005;192:807-12. (Level II-2)
35. Guerriero S, Alcazar JL, Coccia ME, Ajossa S, Scarselli G, Boi M, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med 2002;21:1105-11. (Level II-2)
36. Kurjak A, Jukic S, Kupesic S, Babic D. A combined Doppler and morphopathological study of ovarian tumors. Eur J Obstet Gynecol Reprod Biol 1997;71:147-50. (Level II-3)
37. Komatsu T, Konishi I, Mandai M, Togashi K, Kawakami S, Konishi J, et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology 1996;198:109-15. (Level III)
38. Grab D, Flock F, Stohr I, Nussle K, Rieber A, Fenchel S, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454-9. (Level II-3)
39. Sohaib SA, Mills TD, Sahdev A, Webb JA, Vantrappen PO, Jacobs IJ, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005;60:340-8. (Level II-3)
40. Buist MR, Golding RP, Burger CW, Vermorken JB, Kenemans P, Schutter EM, et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 1994;52:191-8. (Level II-3)
41. Yamashita Y, Torashima M, Hatanaka Y, Harada M, Higashida Y, Takahashi M, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995;194:557-65. (Level II-3)
42. Hricak H, Chen M, Coakley FV, Kinkel K, Yu KK, Sica G, et al. Complex adnexal masses: detection and characterization with MR imaging - multivariate analysis. Radiology 2000;214:39-46. (Level II-3)
43. Chang SD, Cooperberg PL, Wong AD, Llewellyn PA, Bilbey JH. Limited-sequence magnetic resonance imaging in the evaluation of the ultrasonographically indeterminate pelvic mass. Can Assoc Radiol J 2004;55:87-95. (Level II-3)
44. Jacobs IJ, Fay TN, Stabile I, Bridges JE, Oram DH, Grudzinskas JG. The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynaecol 1988;95:1190-4. (Level III)
45. Maggino T, Gadducci A, D'Addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994;54:117-23. (Level II-2)
46. Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G,Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994;74:1398-406. (Level II-3)
47. Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D, Mustea A, et al. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res 2003;23:1115-8. (Level II-2)
48. Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001;81:225-9. (Level III)
49. Alcazar JL, Castillo G, Jurado M, Garcia GL. Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women? Hum Reprod 2005;20:3231-4. (Level II-2)
50. Castillo G, Alcazar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92:965-9. (Level II-2)
51. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102:594-9. (Level II-1)
52. Brown DL, Doubilet PM, Miller FH, Frates MC, Laing FC, DiSalvo DN, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998;208:103-10. (Level II-3)
53. Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 2001;184:48-54. (Level II-2)
54. Guerriero S, Mais V, Ajossa S, Paoletti AM, Angiolucci M, Labate F, et al. The role of endovaginal ultrasound in differentiating endometriomas from other ovarian cysts. Clin Exp Obstet Gynecol 1995;22:20-2. (Level II-2)
55. Kupfer MC, Schwimer SR, Lebovic J. Transvaginal sonographic appearance of endometriomata: spectrum of findings. J Ultrasound Med 1992;11:129-33. (Level III)
56. Ekici E, Soysal M, Kara S, Dogan M, Gokmen O. The efficiency of ultrasonography in the diagnosis of dermoid cysts. Zentralbl Gynakol 1996;118:136-41. (Level II-2)
57. Guerriero S, Ajossa S, Lai MP, Mais V, Paoletti AM, Melis GB. Transvaginal ultrasonography associated with colour Doppler energy in the diagnosis of hydrosalpinx. Hum Reprod 2000;15:1568-72. (Level II-3)
58. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and post-menopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6. (Level II-1)
59. Kitawaki J, Ishihara H, Koshiba H, Kiyomizu M, Teramoto M, Kitaoka Y, et al. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas. Hum Reprod 2005;20:1999-2003. (Level II-2)
60. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21(suppl):206- 10. (Level II-3)
61. Deligeoroglou E, Eleftheriades M, Shiadoes V, Botsis D, Hasiakos D, Kontoravdis A, et al. Ovarian masses during adolescence: clinical, ultrasonographic and pathologic findings, serum tumor markers and endocrinological profile. Gynecol Endocrinol 2004;19:1-8. (Level III)
62. van Winter JT, Simmons PS, Podratz KC. Surgically treated adnexal masses in infancy, childhood, and adolescence. Am J Obstet Gynecol 1994;170:1780-6; discussion 1786-9. (Level III)
63. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355-8. (Level II-2)
64. Moran O, Menczer J, Ben-Baruch G, Lipitz S, Goor E. Cytologic examination of ovarian cyst fluid for the distinction between benign and malignant tumors. Obstet Gynecol 1993;82:444-6. (Level II-3)
65. Higgins RV, Matkins JF, Marroum MC. Comparison of fine-needle aspiration cytologic findings of ovarian cysts with ovarian histologic findings. Am J Obstet Gynecol 1999;180:550-3. (Level II-3)
66. Martinez-Onsurbe P, Ruiz Villaespesa A, Sanz Anquela JM, Valenzuela Ruiz PL. Aspiration cytology of 147 adnexal cysts with histologic correlation. Acta Cytol 2001;45:941-7. (Level III)
67. Gaetje R, Popp LW. Is differentiation of benign and malignant cystic adnexal masses possible by evaluation of cysts fluids with respect to color, cytology, steroid hormones, and tumor markers? Acta Obstet Gynecol Scand 1994;73:502-7. (Level III)
68. Ganjei P, Dickinson B, Harrison T, Nassiri M, Lu Y. Aspiration cytology of neoplastic and non-neoplastic ovarian cysts: is it accurate? Int J Gynecol Pathol 1996;15:94-101. (Level II-3)
69. Vercellini P, Oldani S, Felicetta I, Bramante T, Rognoni MT, Crosignani PG. The value of cyst puncture in the differential diagnosis of benign ovarian tumours. Hum Reprod 1995;10:1465-9. (Level II-3)
70. Bonilla-Musoles F, Ballester MJ, Simon C, Serra V, Raga F. Is avoidance of surgery possible in patients with perimenopausal ovarian tumors using transvaginal ultrasound and duplex color Doppler sonography? J Ultrasound Med 1993;12:33-9. (Level II-3)
71. Perrin RG, Bernstein M. Iatrogenic seeding of anaplastic astrocytoma following stereotactic biopsy. J Neurooncol 1998 Feb;36:243-6. (Level III)
72. Kim JE, Kim CY, Kim DG, Jung HW. Implantation metastasis along the stereotactic biopsy tract in anaplastic astrocytoma: a case report. J Neurooncol 2003;61:215-8. (Level III)
73. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 2003;65:29-36. (Level III)
74. Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994;84:1-7. (Level III)
75. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6. (Level III)
76. Chan YM, Ng TY, Ngan HY,Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16. (Level II-2)
77. Kinkel K, Lu Y, Mehdizade A, Pelte MF, Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization - meta-analysis and Bayesian analysis. Radiology 2005;236:85-94. (Level II-3)
78. Wolfe CD, Tilling K, Raju KS. Management and survival of ovarian cancer patients in south east England. Eur J Cancer. 1997;33:1835-40. (Level II-2)
79. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999;106:1130-6. (Level III)
80. McGowan L, Lesher LP, Norris HJ, Barnett M. Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-72. (Level III)
81. Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41. (Level III)
82. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol 2000;78:S1-13. (Level III)
83. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001;19:2658-64. (Level II-2)
84. Schmeler KM, Mayo-Smith WW, Peipert JF, Weitzen S, Manuel MD, Gordinier ME. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005;105:1098-103. (Level III)
85. Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999;181:19-24. (Level III)
86. Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol 1999;93:585-9. (Level II-3)
87. Platek DN, Henderson CE, Goldberg GL. The management of a persistent adnexal mass in pregnancy. Am J Obstet Gynecol 1995;173:1236-40. (Level III)
88. Bromley B, Benacerraf B. Adnexal masses during pregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med 1997;16:447-52; quiz 453-4. (Level II-3)
89. Sunoo CS, Terada KY, Kamemoto LE, Hale RW. Adnexal masses in pregnancy: occurrence by ethnic group. Obstet Gynecol 1990;75:38-40. (Level III)
90. Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998;43:387-92. (Level II-3)
91. Zanetta G, Mariani E, Lissoni A, Ceruti P, Trio D, Strobelt N, et al. A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy. BJOG 2003;110:578-83. (Level II-2)
92. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005;16:403-10. (Level III)
93. Lecuru F, Desfeux P, Camatte S, Bissery A, Blanc B, Querleu D. Impact of initial surgical access on staging and survival of patients with stage I ovarian cancer. Int J Gynecol Cancer 2006;16:87-94. (Level III)
94. Chi DS, Abu-Rustum NR, Sonoda Y, Ivy J, Rhee E, Moore K, et al. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005;192:1614-9. (Level II-2)
95. Canis M, Mage G, Pouly JL,Wattiez A, Glowaczower E, Raiga J, et al. Laparoscopic management of suspicious adnexal masses [abstract]. J Am Assoc Gynecol Laparosc 1994;1:S6. (Level II-3)
96. Havrilesky LJ, Peterson BL, Dryden DK, Soper JT, Clarke-Pearson DL, Berchuck A. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol 2003;102:243-51. (Level III)
97. Mendilcioglu I, Zorlu CG, Trak B, Ciftci C, Akinci Z. Laparoscopic management of adnexal masses. Safety and effectiveness. J Reprod Med 2002;47:36-40. (Level II-3)
98. Serur E, Emeney PL, Byrne DW. Laparoscopic management of adnexal masses. JSLS 2001;5:143-51. (Level III)
99. Childers JM, Nasseri A, Surwit EA. Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996;175:1451-7; discussion 1457-9. (Level III)
100. Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med 1997;42:551-8. (Level III)
101. Parker WH, Levine RL, Howard FM, Sansone B, Berek JS. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994;179:733-7. (Level II-3)
102. Yuen PM, Yu KM, Yip SK, Lau WC, Rogers MS, Chang A. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 1997;177:109-14. (Level I)
103. Fanfani F, Fagotti A, Ercoli A, Bifulco G, Longo R, Mancuso S, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004;19:2367-71. (Level I)
104. Deckardt R, Saks M, Graeff H. Comparison of minimally invasive surgery and laparotomy in the treatment of adnexal masses. J Am Assoc Gynecol Laparosc 1994;1:333-8. (Level I)
105. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol 1994;84:22-8. (Level III)
106. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-26. (Level II-2)
107. Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000;89:391-8. (Level III)
108. Perrin LC, Low J, Nicklin JL, Ward BG, Crandon AJ. Fertility and ovarian function after conservative surgery for germ cell tumours of the ovary. Aust N Z J Obstet Gynaecol 1999;39:243-5. (Level III)
109. Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility: reproductive performance after persistent remission. Am J Clin Oncol 2000;23:244-8. (Level III)
110. Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 2005;98:263-6. (Level III)
111. Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003;79:1216-21. (Level III)
112. Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003;48:756-60. (Level III)
113. Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005;97:845-51. (Level III)
114. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7. (Level III)
115. Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, et al. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique). GCCLCC and SFOG. Hum Reprod 2005;20:1379-85. (Level III)
116. Canis M, Mashiach R, Wattiez A, Botchorishvili R, Rabischong B, Jardon K, et al. Frozen section in laparoscopic management of macroscopically suspicious ovarian masses. J Am Assoc Gynecol Laparosc 2004;11:365-9. (Level II-3)